VEGFA and renal cell carcinoma: The cabozantinib tablet formulation (CabometyxTM) is approved at a 60-mg-free-base equivalent (FBE) daily dosage for the treatment of patients with advanced RCC in USA who have received prior anti-angiogenic therapy and in the European Union (EU) following prior VEGF-targeted therapy, with dosage adjustments to 40-mg FBE and then 20-mg FBE permitted to manage adverse events (AEs) [12, 13].